These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 3258504)

  • 21. Production of tumour necrosis factor and interleukin 1 by monocytes of patients with previous Yersinia arthritis.
    Repo H; Jäättelä M; Leirisalo-Repo M; Hurme M
    Clin Exp Immunol; 1988 Jun; 72(3):410-4. PubMed ID: 3262459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Yersinia arthritis, immune functions and histocompatibility antigens.
    Repo H; Leirisalo-Repo M; Gripenberg M; Koskimies S; Kontiainen S; Laitinen O
    Acta Pathol Microbiol Immunol Scand C; 1986 Dec; 94(6):245-52. PubMed ID: 2953168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relation between HLA-B27 and clinical features in patients with yersinia arthritis.
    Laitinen O; Leirisalo M; Skylv G
    Arthritis Rheum; 1977 Jun; 20(5):1121-4. PubMed ID: 869958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of HLA type and hypocomplementaemia on the expression of parvovirus arthritis: one year follow up of an outbreak.
    Gendi NS; Gibson K; Wordsworth BP
    Ann Rheum Dis; 1996 Jan; 55(1):63-5. PubMed ID: 8572737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody producing capacity to the bacteriophage phi X174 in yersinia arthritis.
    Bucknall R; Leirisalo-Repo M; Laitinen O; Jones JV
    Ann Rheum Dis; 1987 Dec; 46(12):883-8. PubMed ID: 2962540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HLA phenotypes in patients with rheumatic fever, rheumatic heart disease, and Yersinia arthritis.
    Leirisalo M; Laitinen O; Tiilikainen A
    J Rheumatol Suppl; 1977; 3():78-83. PubMed ID: 266605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement activation during storage of whole blood, red cells, plasma, and buffy coat.
    Hyllner M; Arnestad JP; Bengtson JP; Rydberg L; Bengtsson A
    Transfusion; 1997 Mar; 37(3):264-8. PubMed ID: 9122898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement split products and the pathogenesis of SLE.
    Abramson SB; Weissmann G
    Hosp Pract (Off Ed); 1988 Dec; 23(12):45-56. PubMed ID: 3142905
    [No Abstract]   [Full Text] [Related]  

  • 29. Compartmental distribution of complement activation products in artificial kidneys.
    Cheung AK; Chenoweth DE; Otsuka D; Henderson LW
    Kidney Int; 1986 Jul; 30(1):74-80. PubMed ID: 3489123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased anaphylatoxins (C3a and C4a) in psoriatic sera.
    Ohkohchi K; Takematsu H; Tagami H
    Br J Dermatol; 1985 Aug; 113(2):189-96. PubMed ID: 3875363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complement activation produced by biomaterials.
    Chenoweth DE
    Artif Organs; 1988 Dec; 12(6):508-10. PubMed ID: 3265053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of complement in atopic dermatitis.
    Kapp A; Schöpf E
    Acta Derm Venereol Suppl (Stockh); 1985; 114():152-4. PubMed ID: 3923750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The ischaemic leg as a source of complement activation.
    Bengtson A; Holmberg P; Heideman M
    Br J Surg; 1987 Aug; 74(8):697-700. PubMed ID: 3498527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement activation during liver transplantation.
    Tomasdottir H; Henriksson BA; Bengtson JP; Bengtsson A; Stenqvist O; Persson H
    Transplantation; 1993 Apr; 55(4):799-802. PubMed ID: 8475554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease.
    Belmont HM; Hopkins P; Edelson HS; Kaplan HB; Ludewig R; Weissmann G; Abramson S
    Arthritis Rheum; 1986 Sep; 29(9):1085-9. PubMed ID: 3489467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutrophil function and HLA-B27.
    Repo H; Leirisalo M; Koivuranta P; Osterman T; Kiistala U; Gahmberg CG; Vapaatalo H; Tiilikainen A; Laitinen O
    Br J Rheumatol; 1983 Nov; 22(4 Suppl 2):168-71. PubMed ID: 6606470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement activation and clearance in acute illness and injury: evidence for C5a as a cell-directed mediator of the adult respiratory distress syndrome in man.
    Solomkin JS; Cotta LA; Satoh PS; Hurst JM; Nelson RD
    Surgery; 1985 Jun; 97(6):668-78. PubMed ID: 4002115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relation between complement activation and susceptibility to decompression sickness.
    Ward CA; McCullough D; Fraser WD
    J Appl Physiol (1985); 1987 Mar; 62(3):1160-6. PubMed ID: 3494726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The significance of complement activation in the pathogenesis of hypersensitivity pneumonitis: sequential changes of complement components and chemotactic activities in bronchoalveolar lavage fluids.
    Yoshizawa Y; Nomura A; Ohdama S; Tanaka M; Morinari H; Hasegawa S
    Int Arch Allergy Appl Immunol; 1988; 87(4):417-23. PubMed ID: 2852642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does reduced erythrocyte C3b receptor (CR1) activity contribute to the pathogenesis of yersinia triggered reactive arthritis?
    Lahesmaa R; Eerola E; Toivanen A
    Ann Rheum Dis; 1992 Jan; 51(1):97-100. PubMed ID: 1531747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.